Abstract 485P
Background
Integrins are known to play a crucial role in the adhesion, invasion and migration of tumor cells. Recent studies revealed the association of certain integrin subunits in organotropic metastasis of breast cancer. In this study, we investigated the biological properties associated with different integrin subunits gene expression in CTCs.
Methods
The study included 81 patients with non-metastatic invasive breast carcinoma of no special type (T1-4N0-3M0, all molecular subtypes). Single-cell cDNA libraries were prepared using the Single Cell 3′ Reagent Kit v3.1 and a 10x Genomics Chromium Controller. The ready cDNA libraries were sequenced on NextSeq 500 and NextSeq 2000 (Illumina, USA).
Results
CTCs were identified based on the expression of one or more epithelial markers: KRT5, 7, 8, 14, 18, EPCAM, MUC1 and CDH1 (E-cadherin). In total, expression of 14 integrin subunits was detected in CTCs: nine α-subunits and five β-subunits. In each cell, the combination of different integrin subunits was evaluated, and if complementary α and β-subunits gene expression detected in one cell, we suggested that CTCs potentially could synthesize functionally complete integrin heterodimers. Depending on the combinations of different subunits in CTCs, 455 cells were divided into nine groups. In each group, we assessed the proportion of cells with expression of genes relevant to the most important functions that determine the malignant potential of tumor cells: stemness, EMT, invasion. The most differences were observed in the group of CTCs potentially capable to express the α6β4 heterodimer. Namely, integrins α6- and β4-positive CTCs more frequent expressed stemness (ALDH1A1, CD133, KLF4, MYC) and invasion markers (RAC1, RHOC, ROCK, MMP1,2). A combination of epithelial (KRT 8, 10, 18, 19 and MUC1) with mesenchymal features (absence of EPCAM expression, expression of CDH2, VIM, ZEB1) indicates a hybrid state of EMT.
Conclusions
A novel approach to scRNA sequence analysis has identified subpopulations of CTCs with pronounced biological properties which can play role of "seeds". The simultaneously presence of integrin α6 and β4-subunits in CTCs was associated with stemness, EMT and invasiveness of CTCs in breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Russian Science Foundation (grant #21-15-00140).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
466P - Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
Presenter: Lei Tang
Session: Poster session 04
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04